Recursion Pharmaceuticals Stock Drops 3.3%, Slips 17.3% This Month
Recursion Pharmaceuticals shares declined 3.27% to close at $3.85, underperforming the S&P 500’s 0.33% drop, and have fallen 17.26% over the past month versus the medical sector’s 1.02% loss. Analysts forecast Q4 EPS of -$0.28 (up 47.2% yoy) on $25.5 million revenue (up 460%) and full-year EPS of -$1.59 with $64.62 million in revenue.
1. Recent Share Performance
Recursion Pharmaceuticals closed at $3.85, down 3.27% on the day as the S&P 500 fell 0.33%, the Dow gained 0.10% and the Nasdaq dropped 0.59%. Over the past month, the shares have slid 17.26%, far exceeding the medical sector’s 1.02% loss and outpacing the flat S&P 500.
2. Quarterly Estimates
Analysts project fourth-quarter earnings per share of -$0.28, marking a 47.17% improvement year-over-year, on an anticipated $25.5 million in revenue, which would represent a 460.44% surge compared to the same period last year.
3. Full-Year Projections
For the full fiscal year, consensus estimates call for EPS of -$1.59 and revenue of $64.62 million, reflecting year-over-year changes of +5.92% and +9.83%, respectively.
4. Analyst Consensus and Industry Position
Recent estimate revisions have remained stable, underpinning a consensus ‘Buy’ rating, while the biomedical and genetics industry group ranks within the top 36% of over 250 peer industries.